世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

世界のジェエリック医薬品市場 2018-2022年

Global Generic Drugs Market 2018-2022

IRTNTR21903

 

出版社 出版年月電子版価格 ページ数
TechNavio
テクナビオ
2018年7月US$2,500
シングルユーザライセンス
120

サマリー

この調査レポートは世界のジェエリック医薬品市場を分析・予測したTechNavioの市場調査報告書です。

Description

About Generic Drugs
A generic drug is a medication created to be the equivalent of an existing approved brand-name drug in terms of dosage form, safety, strength, route of administration, quality, and performance characteristics.
Technavio’s analysts forecast the Global Generic Drugs Market to grow at a CAGR of 10.22% during the period 2018-2022.

Covered in this report
The report covers the present scenario and the growth prospects of the generic drugs market. To calculate the market size, the report considers the revenue generated from the sales of generic drugs.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, generic drugs market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Fresenius Kabi
- Mylan
- Novartis
- Pfizer
- Sun Pharmaceutical Industries
- Teva Pharmaceutical Industries


Market driver
- Rising drug patient expirations
- For a full, detailed list, view our report
Market challenge
- Rising credibility issues
- For a full, detailed list, view our report

Market trend
- Rising M&A
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2022 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.



目次

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 05: MARKET SIZING
- Market definition
- Market sizing 2017
- Market size and forecast 2017-2022
PART 06: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 07: MARKET SEGMENTATION BY APPLICATION
- Anti-infectives
- CNS
- Others
PART 08: MARKET SEGMENTATION BY CATEGORY
- Segmentation by category
- Comparison by category
- Small molecule generics - Market size and forecast 2017-2022
- Biosimilars - Market size and forecast 2017-2022
- Market opportunity by category
PART 09: CUSTOMER LANDSCAPE
PART 10: REGIONAL LANDSCAPE
- Geographical segmentation
- Regional comparison
- Americas - Market size and forecast 2017-2022
- APAC - Market size and forecast 2017-2022
- EMEA - Market size and forecast 2017-2022
- Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 13: MARKET TRENDS
- Advent of RPA
- Rising M&A
- Hospital-owned generics
PART 14: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 15: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Fresenius Kabi
- Mylan
- Novartis
- Pfizer
- Sun Pharmaceutical Industries
- Teva Pharmaceutical Industries
PART 16: APPENDIX
- List of abbreviations


-
Exhibit 01: Global pharmaceutical market: Market size
Exhibit 02: Global pharmaceutical market: Segmentation
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global generic drugs market - Market size and forecast 2017-2022 ($ bn)
Exhibit 09: Global generic drugs market - Year over year growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Global generic drugs market by category - Market share 2017-2022 (%)
Exhibit 19: Comparison by category
Exhibit 20: Global generic drugs market by small molecule generics - Market size and forecast 2017-2022 ($ bn)
Exhibit 21: Global generic drugs market by small molecule generics - Year over year growth 2018-2022 (%)
Exhibit 22: Global generic drugs market by biosimilars - Market size and forecast 2017-2022 ($ bn)
Exhibit 23: Global generic drugs market by biosimilars - Year over year growth 2018-2022 (%)
Exhibit 24: Market opportunity by category
Exhibit 25: Customer landscape
Exhibit 26: Global generic drugs market by region - Market share 2017-2022 (%)
Exhibit 27: Regional comparison
Exhibit 28: Generic drugs market in Americas - Market size and forecast 2017-2022 ($ bn)
Exhibit 29: Generic drugs market in Americas - Year over year growth 2018-2022 (%)
Exhibit 30: Top three countries in Americas
Exhibit 31: Generic drugs market in APAC - Market size and forecast 2017-2022 ($ bn)
Exhibit 32: Generic drugs market in APAC - Year over year growth 2018-2022 (%)
Exhibit 33: Top three countries in APAC
Exhibit 34: Generic drugs market in EMEA - Market size and forecast 2017-2022 ($ bn)
Exhibit 35: Generic drugs market in EMEA - Year over year growth 2018-2022 (%)
Exhibit 36: Top three countries in EMEA
Exhibit 37: Market opportunity
Exhibit 38: Exhibit: Drug patent expirations in 2018
Exhibit 39: Vendor landscape
Exhibit 40: Landscape disruption
Exhibit 41: Vendors covered
Exhibit 42: Vendor classification
Exhibit 43: Market positioning of vendors
Exhibit 44: Fresenius Kabi overview
Exhibit 45: Fresenius Kabi - Business segments
Exhibit 46: Fresenius Kabi - Organizational developments
Exhibit 47: Fresenius Kabi - Geographic focus
Exhibit 48: Fresenius Kabi - Segment focus
Exhibit 49: Fresenius Kabi - Key offerings
Exhibit 50: Mylan overview
Exhibit 51: Mylan - Business segments
Exhibit 52: Mylan - Organizational developments
Exhibit 53: Mylan - Segment focus
Exhibit 54: Mylan - Key offerings
Exhibit 55: Novartis overview
Exhibit 56: Novartis - Business segments
Exhibit 57: Novartis - Organizational developments
Exhibit 58: Novartis - Geographic focus
Exhibit 59: Novartis - Segment focus
Exhibit 60: Novartis - Key offerings
Exhibit 61: Pfizer overview
Exhibit 62: Pfizer - Business segments
Exhibit 63: Pfizer - Organizational developments
Exhibit 64: Pfizer - Geographic focus
Exhibit 65: Pfizer - Segment focus
Exhibit 66: Pfizer - Key offerings
Exhibit 67: Sun Pharmaceutical Industries overview
Exhibit 68: Sun Pharmaceutical Industries - Business segments
Exhibit 69: Sun Pharmaceutical Industries - Organizational developments
Exhibit 70: Sun Pharmaceutical Industries - Geographic focus
Exhibit 71: Sun Pharmaceutical Industries - Segment focus
Exhibit 72: Sun Pharmaceutical Industries - Key offerings
Exhibit 73: Teva Pharmaceutical Industries overview
Exhibit 74: Teva Pharmaceutical Industries - Business segments
Exhibit 75: Teva Pharmaceutical Industries - Organizational developments
Exhibit 76: Teva Pharmaceutical Industries - Geographic focus
Exhibit 77: Teva Pharmaceutical Industries - Segment focus
Exhibit 78: Teva Pharmaceutical Industries - Key offerings




 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る